Oak Ridge Investments’s Viking Therapeutics VKTX Stock Holding History

Oak Ridge Investments’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$479K	Buy	12,291 +266	+2%	+$8.59K	0.03%	149
2026 Q1	$391K	Buy	12,025 +439	+4%	+$14.1K	0.03%	152
2025 Q4	$408K	Sell	11,586 -625	-5%	-$22.1K	0.02%	153
2025 Q3	$321K	Sell	12,211 -153	-1%	-$4.56K	0.02%	163
2025 Q2	$328K	Sell	12,364 -586	-5%	-$15.4K	0.02%	159
2025 Q1	$313K	Buy	12,950 +1,928	+17%	+$60.9K	0.03%	155
2024 Q4	$444K	Sell	11,022 -2,200	-17%	-$125K	0.03%	149
2024 Q3	$837K	Buy	+13,222	New	+$776K	0.07%	120

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Oak Ridge Investments's VKTX Position: Q2 2026 in Review

Oak Ridge Investments increased its Viking Therapeutics (VKTX) stake by 2.2% in Q2 2026, buying an estimated $8.59K and bringing the position to 12,291 shares worth $479K. The position accounts for 0.03% of the portfolio, ranked #149.

Oak Ridge Investments first reported a position in VKTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $837K in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Oak Ridge Investments held 12,291 shares of Viking Therapeutics worth $479K as of Q2 2026.
Oak Ridge Investments bought 266 Viking Therapeutics shares in Q2 2026, an estimated $8.59K.
Viking Therapeutics made up 0.03% of Oak Ridge Investments's portfolio in Q2 2026, its #149 holding.
Oak Ridge Investments first reported a position in Viking Therapeutics in Q3 2024 and has held it in 8 quarters since.
Oak Ridge Investments's Viking Therapeutics position peaked at $837K in Q3 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Oak Ridge Investments's 13F filing for Q2 2026, filed 21 Jul 2026.